title: [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival].
abstract: Ubenimex was concurrently administered to 18 elderly patients with acute myelocytic leukemia (AML), and a chemotherapy protocol was prepared corresponding to patient age and organ disorders. The dose-reduced protocol of the Japan Adult Leukemia Study Group (JALSG) '95 or aclarubicin 14 mg/m2 day 1-4, cytosine arabinoside 15 mg/m2 day 1-14, granulocyte colony stimulating factor (G-CSF) 150 micrograms/body day 1-14 (CAG therapy) were administered. In addition, ubenimex 30 mg/day was administered orally after induction of remission. As per the JALSG protocol for dose reduction when organ disorder is absent, 85% and 70% of the dose were administered to the patients aged 65-69 years and 70-74 years, respectively. For patients aged 75 years or more and patients with mild disorders of the heart, kidney, and liver, CAG therapy was administered. As a result, the complete remission (CR) rate was 67%, and the three-year survival rate was 32%. This protocol may be useful for elderly AML.
authors.affiliation: Dept. of Internal Medicine, Higashi-Sapporo Hospital.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirayama
authors.forename: Sumio
authors.initials: S
authors.lastname: Sakamaki
authors.forename: Norihiro
authors.initials: N
authors.lastname: Takayanagi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tsuji
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Sagawa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Chiba
authors.forename: Takuya
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007930:Leucine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin; D007930:Leucine; C012211:ubenimex